The estimated Net Worth of Matthew M Walsh is at least $2.31 million dollars as of 21 May 2024. Matthew Walsh owns over 8,663 units of Certara stock worth over $2,038,228 and over the last 10 years Matthew sold CERT stock worth over $267,702.
Matthew has made over 13 trades of the Certara stock since 2015, according to the Form 4 filled with the SEC. Most recently Matthew exercised 8,663 units of CERT stock worth $95,120 on 21 May 2024.
The largest trade Matthew's ever made was exercising 102,043 units of Certara stock on 6 April 2015 worth over $1,092,881. On average, Matthew trades about 15,052 units every 106 days since 2015. As of 21 May 2024 Matthew still owns at least 185,631 units of Certara stock.
You can see the complete history of Matthew Walsh stock trades at the bottom of the page.
Matthew's mailing address filed with the SEC is C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON, NJ, 08540.
Over the last 5 years, insiders at Certara have traded over $2,048,278,243 worth of Certara stock and bought 97,245 units worth $1,908,085 . The most active insiders traders include Avatar Parent L.P.Eqt Avata..., James E Iii Cashman et Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of $7,828,136. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth $578,319.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara executives and other stock owners filed with the SEC include: